{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T06:33:46Z","timestamp":1787639626033,"version":"build-2736575974"},"reference-count":91,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jbspin.2025.105972","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T23:32:21Z","timestamp":1758065541000},"page":"105972","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Skin cancer risk in patients with non-dermatologic immune-mediated inflammatory diseases"],"prefix":"10.1016","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2793-6303","authenticated-orcid":false,"given":"Jean-Guillaume","family":"Letarouilly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Wils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Staumont-Sall\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Jullien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Mortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Richez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Boileau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9-Marc","family":"Flipo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2025.105972_bib0460","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1038\/s41598-021-83502-8","article-title":"The incidence and clinical analysis of non-melanoma skin cancer","volume":"11","author":"Ci\u0105\u017cy\u0144ska","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jbspin.2025.105972_bib0465","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejca.2019.06.003","article-title":"Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines","volume":"118","author":"Peris","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jbspin.2025.105972_bib0470","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2020.01.007","article-title":"European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. Epidemiology, diagnostics and prevention","volume":"128","author":"Stratigos","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jbspin.2025.105972_bib0475","doi-asserted-by":"crossref","first-page":"8984","DOI":"10.3390\/ijms21238984","article-title":"Overcoming immune evasion in melanoma","volume":"21","author":"Eddy","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jbspin.2025.105972_bib0480","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/bjd.13403","article-title":"Clinical practice guidelines for identification, screening and follow-up of individuals at high risk of primary cutaneous melanoma: a systematic review","volume":"172","author":"Watts","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0485","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2022.11.043","article-title":"Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: methotrexate, alkylating agents, biologics, and small molecule inhibitors","volume":"88","author":"Kreher","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0490","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1001\/jama.2023.3262","article-title":"Skin cancer screening: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"329","author":"Henrikson","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jbspin.2025.105972_bib0495","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjd.20658","article-title":"Are patients benefiting from participation in the German skin cancer screening programme? A large cohort study based on administrative data","volume":"186","author":"Datzmann","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0500","first-page":"629","article-title":"Skin cancer screening in Germany. Documenting melanoma incidence and mortality from 2008 to 2013","volume":"112","author":"Katalinic","year":"2015","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.jbspin.2025.105972_bib0505","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10198-017-0888-4","article-title":"The effectiveness of a population-based skin cancer screening program: evidence from Germany","volume":"19","author":"Kaiser","year":"2018","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jbspin.2025.105972_bib0510","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/bmjebm-2023-112341","article-title":"Overdiagnosis in malignant melanoma: a scoping review","volume":"29","author":"Bj\u00f8rch","year":"2024","journal-title":"BMJ Evid Based Med"},{"key":"10.1016\/j.jbspin.2025.105972_bib0515","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1016\/j.jaad.2023.05.095","article-title":"Response to the feasibility of Kreher et al.\u2019s \u201cRisk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: methotrexate, alkylating agents, biologics, and small molecule inhibitors\u201d","volume":"89","author":"Rypka","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0520","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/ijc.30183","article-title":"Inflammatory bowel disease, cancer and medication: cancer risk in the Dutch population-based IBDSL cohort","volume":"139","author":"van den Heuvel","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jbspin.2025.105972_bib0525","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/ajg.2009.760","article-title":"Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies","volume":"105","author":"Pedersen","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0530","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/ecco-jcc\/jjv032","article-title":"Incidence, management, and course of cancer in patients with inflammatory bowel disease","volume":"9","author":"Algaba","year":"2015","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jbspin.2025.105972_bib0535","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.cgh.2013.03.034","article-title":"Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation","volume":"12","author":"Kappelman","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0540","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","article-title":"Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease","volume":"143","author":"Long","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jbspin.2025.105972_bib0545","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1053\/j.gastro.2011.07.039","article-title":"Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease","volume":"141","author":"Singh","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jbspin.2025.105972_bib0550","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.cgh.2013.04.033","article-title":"Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis","volume":"12","author":"Singh","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0555","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/apt.16677","article-title":"Surgery, cancer and mortality among patients with ulcerative colitis diagnosed 1962\u20131987 and followed until 2017 in a Danish population-based inception cohort","volume":"55","author":"Burisch","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jbspin.2025.105972_bib0560","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2025.105972_bib0565","doi-asserted-by":"crossref","first-page":"e002874","DOI":"10.1136\/rmdopen-2022-002874","article-title":"Risk of cancer in Korean patients with psoriatic arthritis: a nationwide population-based cohort study","volume":"9","author":"Eun","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2025.105972_bib0570","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1093\/rheumatology\/keaa166","article-title":"Risks of solid cancers in elderly persons with osteoarthritis or ankylosing spondylitis","volume":"59","author":"Ward","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2025.105972_bib0575","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s41927-022-00275-x","article-title":"Malignancy in ankylosing spondylitis: a cross-sectional analysis of a large population database","volume":"6","author":"Bittar","year":"2022","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0580","doi-asserted-by":"crossref","first-page":"100768","DOI":"10.1016\/j.lanepe.2023.100768","article-title":"Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort study","volume":"35","author":"Beydon","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jbspin.2025.105972_bib0585","first-page":"110","article-title":"Risk of malignant melanoma and non-melanoma skin cancer in rheumatoid arthritis patients initiating methotrexate versus hydroxychloroquine: a cohort study","volume":"41","author":"Lee","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0590","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1001\/jamadermatol.2022.3337","article-title":"Association between low-dose methotrexate exposure and melanoma: a systematic review and meta-analysis","volume":"158","author":"Yan","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0595","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/s41416-023-02172-7","article-title":"Use of methotrexate and risk of skin cancer: a nationwide case-control study","volume":"128","author":"Polesie","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jbspin.2025.105972_bib0600","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamadermatol.2015.3029","article-title":"Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer","volume":"152","author":"Scott","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0605","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/acr2.11187","article-title":"Adverse effects of low-dose methotrexate in a randomized double-blind placebo-controlled trial: adjudicated hematologic and skin cancer outcomes in the cardiovascular inflammation reduction trial","volume":"2","author":"Vanni","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0610","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jbspin.2025.105972_bib0615","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/apt.14688","article-title":"Systematic review: safety of mesalazine in ulcerative colitis","volume":"47","author":"Sehgal","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jbspin.2025.105972_bib0620","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO Guidelines on therapeutics in Crohn's disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jbspin.2025.105972_bib0625","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/MIB.0000000000000457","article-title":"Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: a Quebec Claims Database Study","volume":"21","author":"Kopylov","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jbspin.2025.105972_bib0630","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ajg.2012.181","article-title":"Risk of melanoma in patients who receive thiopurines for inflammatory bowel disease is not increased","volume":"107","author":"Peyrin-Biroulet","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0635","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/ajg.2014.298","article-title":"Risk of melanoma and non-melanoma skin cancer in ulcerative colitis patients treated with thiopurines: a nationwide retrospective cohort","volume":"109","author":"Abbas","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0640","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1440-1746.2011.06865.x","article-title":"Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study","volume":"27","author":"Setshedi","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0645","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/jgh.14533","article-title":"Risk of skin cancers in thiopurines-treated and thiopurines-untreated patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"34","author":"Huang","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0650","doi-asserted-by":"crossref","first-page":"267","DOI":"10.15403\/jgld.2014.1121.233.mrmk","article-title":"Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-\u03b1 inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System","volume":"23","author":"McKenna","year":"2014","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1016\/j.jbspin.2025.105972_bib0655","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cgh.2009.11.024","article-title":"Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease","volume":"8","author":"Long","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0660","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/ajg.2013.451","article-title":"Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis","volume":"109","author":"Ariyaratnam","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0665","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1053\/j.gastro.2011.06.050","article-title":"Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease","volume":"141","author":"Peyrin-Biroulet","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jbspin.2025.105972_bib0670","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/jdv.14105","article-title":"Increased non-melanoma skin cancer risk in young patients with inflammatory bowel disease on immunomodulatory therapy: a retrospective single-centre cohort study","volume":"31","author":"Clowry","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0675","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/DSS.0000000000001455","article-title":"Nonmelanoma skin cancer risk in patients with inflammatory bowel disease undergoing thiopurine therapy: a systematic review of the literature","volume":"44","author":"Hagen","year":"2018","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jbspin.2025.105972_bib0680","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/jgh.14041","article-title":"The risk of non-melanoma skin cancer in New Zealand in inflammatory bowel disease patients treated with thiopurines","volume":"33","author":"Bahi","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0685","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/ibd\/izac171","article-title":"Risks of melanoma and nonmelanoma skin cancers pre- and post-inflammatory bowel disease diagnosis","volume":"29","author":"Narous","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jbspin.2025.105972_bib0690","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/bjd.12779","article-title":"Melanoma associated with tumour necrosis factor-\u03b1 inhibitors: a Research on Adverse Drug events And Reports (RADAR) project","volume":"170","author":"Nardone","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0695","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/jamadermatol.2020.1300","article-title":"Melanoma risk in patients treated with biologic therapy for common inflammatory diseases: a systematic review and meta-analysis","volume":"156","author":"Esse","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0700","doi-asserted-by":"crossref","first-page":"f1939","DOI":"10.1136\/bmj.f1939","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden","volume":"346","author":"Raaschou","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2025.105972_bib0705","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/CMR.0000000000000284","article-title":"Melanoma risk in patients with rheumatoid arthritis treated with tumour necrosis factor alpha inhibitors: a systematic review and meta-analysis","volume":"26","author":"Olsen","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jbspin.2025.105972_bib0710","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/annrheumdis-2016-209270","article-title":"Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers","volume":"76","author":"Hellgren","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105972_bib0715","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pds.2046","article-title":"Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data","volume":"20","author":"Askling","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jbspin.2025.105972_bib0720","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2012-201969","article-title":"Incidences of overall and site specific cancers in TNF\u03b1 inhibitor treated patients with rheumatoid arthritis and other arthritides\u00a0\u2013\u00a0a follow-up study from the DANBIO Registry","volume":"72","author":"Dreyer","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105972_bib0725","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/art.22864","article-title":"Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2025.105972_bib0730","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/rheumatology\/ker113","article-title":"Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis","volume":"50","author":"Amari","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2025.105972_bib0735","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1136\/annrheumdis-2011-200622","article-title":"The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register","volume":"71","author":"Mercer","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105972_bib0740","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1136\/ard.2010.149419","article-title":"Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis","volume":"70","author":"Mariette","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105972_bib0745","doi-asserted-by":"crossref","first-page":"i262","DOI":"10.1136\/bmj.i262","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden","volume":"352","author":"Raaschou","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2025.105972_bib0750","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/annrheumdis-2016-209285","article-title":"Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers","volume":"76","author":"Mercer","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105972_bib0755","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.semarthrit.2013.08.003","article-title":"Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs","volume":"43","author":"Solomon","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2025.105972_bib0760","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/jamainternmed.2017.4332","article-title":"Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study From Sweden","volume":"177","author":"Wadstr\u00f6m","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jbspin.2025.105972_bib0765","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMe058166","article-title":"Immunosuppression\u00a0\u2014\u00a0The promise of specificity","volume":"353","author":"Ingelfinger","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2025.105972_bib0770","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1093\/rheumatology\/kez604","article-title":"Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study","volume":"59","author":"de Germay","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2025.105972_bib0775","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/ard-2023-224356","article-title":"Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis: a comprehensive evaluation of randomised controlled trials and observational studies","volume":"83","author":"Simon","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105972_bib0780","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.semarthrit.2019.03.002","article-title":"Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: a multi-database cohort study","volume":"49","author":"Kim","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2025.105972_bib0785","doi-asserted-by":"crossref","first-page":"e000213","DOI":"10.1136\/rmdopen-2015-000213","article-title":"Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab","volume":"2","author":"Rubbert-Roth","year":"2016","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2025.105972_bib0790","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn's disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.jbspin.2025.105972_bib0795","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1007\/s10620-021-07073-4","article-title":"Risk of malignancy with vedolizumab versus tumor necrosis factor-\u03b1 antagonists in patients with inflammatory bowel diseases","volume":"67","author":"Singh","year":"2022","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jbspin.2025.105972_bib0800","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.cgh.2018.09.035","article-title":"Retrospective analysis of safety of vedolizumab in patients with inflammatory bowel diseases","volume":"17","author":"Meserve","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0805","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1007\/s12325-021-01713-x","article-title":"Incidence of infections and malignancy among elderly male patients with IBD exposed to vedolizumab, prednisone, and 5-ASA medications: a nationwide retrospective cohort study","volume":"38","author":"Khan","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.jbspin.2025.105972_bib0810","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1093\/rheumatology\/keaa189","article-title":"Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials","volume":"59","author":"Genovese","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2025.105972_bib0815","doi-asserted-by":"crossref","first-page":"adv00698","DOI":"10.2340\/actadv.v102.563","article-title":"Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data","volume":"102","author":"Gottlieb","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0820","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s13555-023-00966-4","article-title":"Integrated safety analysis on skin cancers among patients with psoriasis receiving ixekizumab in clinical trials","volume":"13","author":"Smith","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jbspin.2025.105972_bib0825","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/1346-8138.15343","article-title":"Long-term safety of brodalumab in Japanese patients with plaque psoriasis: an open-label extension study","volume":"47","author":"Yamaguchi","year":"2020","journal-title":"J Dermatol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0830","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.12214","article-title":"Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up","volume":"168","author":"Papp","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0835","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/jdv.12046","article-title":"Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study","volume":"27","author":"Kimball","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0840","first-page":"1059","article-title":"Non-melanoma skin cancer risk among patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"18","author":"deShazo","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0845","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/ibd\/izaa236","article-title":"Safety of ustekinumab in inflammatory bowel disease: pooled safety analysis of results from phase 2\/3 studies","volume":"27","author":"Sandborn","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jbspin.2025.105972_bib0850","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.cgh.2021.02.025","article-title":"Five-year efficacy and safety of ustekinumab treatment in Crohn's disease: the IM-UNITI Trial","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0855","doi-asserted-by":"crossref","first-page":"i433","DOI":"10.1093\/ecco-jcc\/jjab232.583","article-title":"P456 Risk of malignant tumors in patients with autoimmune diseases on ustekinumab therapy: a systematic review and meta-analysis","volume":"16","author":"Huang","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jbspin.2025.105972_bib0860","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1007\/s12325-023-02568-0","article-title":"Safety of IL-23 p19 inhibitors for the treatment of patients with moderate-to-severe plaque psoriasis: a narrative review","volume":"40","author":"Blauvelt","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.jbspin.2025.105972_bib0865","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2025.105972_bib0870","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/bjd.20818","article-title":"Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis","volume":"186","author":"Gordon","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0875","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaad.2023.03.035","article-title":"Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: pooled results from the VOYAGE 1 and VOYAGE 2 trials","volume":"89","author":"Blauvelt","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0880","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2025.105972_bib0885","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/ard-2023-224049","article-title":"JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications","volume":"82","author":"Russell","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105972_bib0890","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/ard-2022-223636","article-title":"Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study","volume":"82","author":"Huss","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105972_bib0895","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s11096-023-01634-5","article-title":"Analysis of the association between Janus kinase inhibitors and malignant skin tumors using the Food and Drug Administration Adverse Event Reporting System","volume":"45","author":"Liu","year":"2023","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.jbspin.2025.105972_bib0900","first-page":"130","article-title":"Early detection of malignant melanoma: the role of physician examination and self-examination of the skin","volume":"35","author":"Friedman","year":"1985","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jbspin.2025.105972_bib0905","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1001\/archderm.134.1.103-a","article-title":"The \u201cugly duckling\u201d sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening","volume":"134","author":"Grob","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jbspin.2025.105972_bib0910","doi-asserted-by":"crossref","first-page":"2313896","DOI":"10.1155\/2022\/2313896","article-title":"Development and validation of a simple model to predict the risk of nonmelanoma skin cancer on screening total body skin examination","volume":"2022","author":"Hartman","year":"2022","journal-title":"Dermatol Res Pract"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X25001344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X25001344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T15:38:38Z","timestamp":1767800318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X25001344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1297319X25001344"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2025.105972","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Skin cancer risk in patients with non-dermatologic immune-mediated inflammatory diseases","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2025.105972","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 Fran\u00e7aise de Rhumatologie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105972"}}